[Clinical experiences with the use of a new antibiotic in inflammatory diseases of surgical interest].
Therapeutic and prophylactic management of 23 adults with inflammation of surgical interest using a new antibiotic, cefalexin sodium (Glaxo). 1.5-6 g/day were administered either i.m. (2 cases) or i.v. (21 cases) for 4 to 13 days. Examinations carried out before and after treatment showed that no damage was caused to the liver, kidney or haematopoietic apparatus. The clinical pharmacokinetic data made it clear that high serum levels were reached and renal elimination of the drug was almost complete. Cepoven displayed a high therapeutic capacity in nearly all cases. Both general and local tolerance were excellent.
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy* / Q000209:etiology; D002506:Cephalexin / Q000627:therapeutic use*; D002764:Cholecystitis / Q000150:complications / Q000601:surgery; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006552:Hernia, Inguinal / Q000150:complications / Q000601:surgery; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications / Q000601:surgery; D008297:Male; D008875:Middle Aged
D002506:Cephalexin
Experienze cliniche sull'uso di un nuovo antibiotico in affezioni flogistiche di interesse chirurgico